204 related articles for article (PubMed ID: 15200421)
1. Parenteral iron nephrotoxicity: potential mechanisms and consequences.
Zager RA; Johnson AC; Hanson SY
Kidney Int; 2004 Jul; 66(1):144-56. PubMed ID: 15200421
[TBL] [Abstract][Full Text] [Related]
2. Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury.
Johnson AC; Becker K; Zager RA
Am J Physiol Renal Physiol; 2010 Aug; 299(2):F426-35. PubMed ID: 20504881
[TBL] [Abstract][Full Text] [Related]
3. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury.
Zager RA; Johnson AC; Hanson SY; Wasse H
Am J Kidney Dis; 2002 Jul; 40(1):90-103. PubMed ID: 12087566
[TBL] [Abstract][Full Text] [Related]
4. Radiographic contrast media-induced tubular injury: evaluation of oxidant stress and plasma membrane integrity.
Zager RA; Johnson AC; Hanson SY
Kidney Int; 2003 Jul; 64(1):128-39. PubMed ID: 12787403
[TBL] [Abstract][Full Text] [Related]
5. Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy.
Zager RA
Kidney Int; 2005 Oct; 68(4):1533-42. PubMed ID: 16164630
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of glutathione and cysteine on Fe2+, Fe3+, H2O2 and myoglobin-induced proximal tubular cell attack.
Zager RA; Burkhart KM
Kidney Int; 1998 Jun; 53(6):1661-72. PubMed ID: 9607198
[TBL] [Abstract][Full Text] [Related]
7. Calcitriol directly sensitizes renal tubular cells to ATP-depletion- and iron-mediated attack.
Zager RA
Am J Pathol; 1999 Jun; 154(6):1899-909. PubMed ID: 10362817
[TBL] [Abstract][Full Text] [Related]
8. Polyene antibiotics: relative degrees of in vitro cytotoxicity and potential effects on tubule phospholipid and ceramide content.
Zager RA
Am J Kidney Dis; 2000 Aug; 36(2):238-49. PubMed ID: 10922301
[TBL] [Abstract][Full Text] [Related]
9. Atractyloside nephrotoxicity: in vitro studies with suspensions of rat renal fragments and precision-cut cortical slices.
Obatomi DK; Bach PH
In Vitr Mol Toxicol; 2000; 13(1):25-36. PubMed ID: 10900405
[TBL] [Abstract][Full Text] [Related]
10. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
[TBL] [Abstract][Full Text] [Related]
11. Plasma membrane cholesterol: a critical determinant of cellular energetics and tubular resistance to attack.
Zager RA
Kidney Int; 2000 Jul; 58(1):193-205. PubMed ID: 10886564
[TBL] [Abstract][Full Text] [Related]
12. Iron, heme oxygenase, and glutathione: effects on myohemoglobinuric proximal tubular injury.
Zager RA; Burkhart KM; Conrad DS; Gmur DJ
Kidney Int; 1995 Nov; 48(5):1624-34. PubMed ID: 8544424
[TBL] [Abstract][Full Text] [Related]
13. Parenteral iron therapy exacerbates experimental sepsis.
Zager RA; Johnson AC; Hanson SY
Kidney Int; 2004 Jun; 65(6):2108-12. PubMed ID: 15149323
[TBL] [Abstract][Full Text] [Related]
14. Comparative toxicity and cell-tissue distribution study on nanoparticular iron complexes using avian embryos and HepG2-cells.
Roth S; Langguth P; Spicher K; Enzmann H
Transl Res; 2008 Jan; 151(1):36-44. PubMed ID: 18061126
[TBL] [Abstract][Full Text] [Related]
15. Acute injury with intravenous iron and concerns regarding long-term safety.
Bishu K; Agarwal R
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
[TBL] [Abstract][Full Text] [Related]
16. Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease.
Zager RA
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S24-31. PubMed ID: 17699373
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
Auerbach M; Al Talib K
Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
[TBL] [Abstract][Full Text] [Related]
18. Maleate nephrotoxicity: mechanisms of injury and correlates with ischemic/hypoxic tubular cell death.
Zager RA; Johnson AC; Naito M; Bomsztyk K
Am J Physiol Renal Physiol; 2008 Jan; 294(1):F187-97. PubMed ID: 17942567
[TBL] [Abstract][Full Text] [Related]
19. P glycoprotein-mediated cholesterol cycling determines proximal tubular cell viability.
Zager RA
Kidney Int; 2001 Sep; 60(3):944-56. PubMed ID: 11532089
[TBL] [Abstract][Full Text] [Related]
20. Heme protein-induced tubular cytoresistance: expression at the plasma membrane level.
Zager RA
Kidney Int; 1995 May; 47(5):1336-45. PubMed ID: 7637263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
